ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC) from a buy rating to a strong-buy rating in a research note released on Wednesday morning.

A number of other equities analysts also recently issued reports on the stock. Roth Mkm raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. HC Wainwright lifted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

ChromaDex Trading Down 1.6 %

NASDAQ:CDXC opened at $5.52 on Wednesday. The company has a 50 day simple moving average of $6.05 and a two-hundred day simple moving average of $4.15. The company has a market cap of $421.63 million, a PE ratio of 552.55 and a beta of 2.16. ChromaDex has a 12 month low of $1.36 and a 12 month high of $7.97.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The company had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter in the prior year, the business earned ($0.01) earnings per share. Research analysts forecast that ChromaDex will post 0.04 earnings per share for the current year.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in ChromaDex by 11.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after buying an additional 33,150 shares in the last quarter. Franklin Resources Inc. bought a new position in shares of ChromaDex in the third quarter worth about $68,000. Barclays PLC grew its position in shares of ChromaDex by 322.1% during the third quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after purchasing an additional 53,472 shares in the last quarter. Geode Capital Management LLC grew its position in shares of ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock worth $4,197,000 after purchasing an additional 17,963 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in ChromaDex by 100.3% during the 3rd quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock valued at $167,000 after purchasing an additional 22,889 shares during the period. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.